)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Panbela Therapeutics
Panbela Therapeutics (PBLA) investor relations material
Panbela Therapeutics has been otc
Panbela Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary14 Nov, 2024
Executive summary
Secured up to $12 million in strategic financing from Nant Capital, with $2.85 million funded and $9.15 million expected by November 15, 2024, supporting financial stability, clinical alliances, and potential immunotherapy collaborations.
Advanced multiple clinical programs, including the pivotal Phase III ASPIRE trial in metastatic pancreatic cancer, with full enrollment expected by Q2 2025 and interim analysis in Q1 2025.
Achieved milestones in the Flynpovi PACES trial for colorectal cancer prevention, with data readout anticipated in the second half of 2026.
Expanded research collaborations and preclinical programs, including partnerships with MD Anderson, Vanderbilt, and ImmunityBio, and initiated new trials in ovarian, lung, and STK11 mutant NSCLC.
Delisted from Nasdaq in April 2024; shares now quoted on OTCQB, with relisting application pending.
Financial highlights
Net loss for Q3 2024 was $7.2 million ($1.48 per diluted share), compared to $7.8 million ($53.74 per diluted share) in Q3 2023; net loss for the nine months ended September 30, 2024, was $21.4 million.
Research and development expenses were $6.0 million in Q3 2024, down from $6.7 million year-over-year; general and administrative expenses were flat at $1.1 million.
Cash as of September 30, 2024, was $142,000, not including the Nant Capital funding; cash position declined from $2.6 million at year-end 2023.
Total current assets were $5.2 million; current liabilities were $20.1 million at quarter end.
Cash used in operations for the nine months ended September 30, 2024, was $12.5 million.
Outlook and guidance
Interim analysis for the ASPIRE trial is expected in Q1 2025, with full enrollment by Q2 2025.
Data readout for the PACES trial is anticipated in the second half of 2026.
Phase II ovarian and neoadjuvant pancreatic cancer trials are planned to open in early 2025.
Company expects to continue incurring substantial losses and negative cash flows as it advances clinical programs.
Additional capital is required immediately to fund operations and complete clinical trials; no assurance of obtaining financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Panbela Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company's lead programs target pancreatic cancer and other gastrointestinal cancers, with an emphasis on inhibiting tumor growth and improving patient outcomes. Panbela’s approach involves advancing small-molecule therapeutics that address significant unmet medical needs in oncology, aiming to provide more effective treatment options for aggressive cancers. The company is headquartered in Waconia, Minnesota, USA, and its shares are listed on the NASDAQ.